APUSHealthcare · Drug Manufacturers - Specialty & Generic

APUS Stock Forecast: Apimeds Pharmaceuticals US, Inc. Price Predictions for 2026-2027

Last close, 7 Oct 2026

$7.05

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 12 of 100 as at 7 Oct 2026 — in the weakest quartile.

Market cap

$6.9M

Ticker Nerd rank

12 / 100

Median analyst target

—

Analysts covering

—

Revenue$0.0

Operating income−$6.3M

Net income−$20.2M

Free cash flow−$5.7M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Ticker Nerd rank

APUS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Apimeds Pharmaceuticals US, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 7 Oct 2026

12 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Volatility

Accruals

Quality

Value

Revisions

Momentum

Issuance

Growth

Size (92): Smaller than most of the companies we track.

Growth (9): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

APUS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on APUS, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. APUS appears on the weeks it earns a place.

Estimates

APUS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Apimeds Pharmaceuticals US, Inc. (APUS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −0.8×
Price / sales: —
Price / book: 7.1×
EV / EBITDA: −1.1×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −3.9%
Return on assets: −3.7%
Dividend yield: 0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Apimeds Pharmaceuticals US, Inc. (APUS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Apimeds Pharmaceuticals US, Inc. has a market value of $6.9M and an enterprise value of $13.1M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$58.2M.
Free cash flow in the twelve months to 30 June 2026: −$13.3M.
Shares outstanding: 150,911.
Trailing P/E: −0.8×.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Apimeds Pharmaceuticals US, Inc. employs 2 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 6 Oct 2026

Data provided by Twelve Data

Peers

APUS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic

Company	Market cap	TKN rank
APUSApimeds Pharmaceuticals US, Inc.	$6.9M	12
BFRIBiofrontera, Inc.	$13.9M	67
INMInMed Pharmaceuticals, Inc.	$7.3M	40
GELSGelteq Ltd.	$6.0M	11
SNOASonoma Pharmaceuticals, Inc.	$5.8M	35
UPCUniverse Pharmaceuticals, Inc.	$21.6M	32
AYTUAytu Biopharma, Inc.	$22.0M	88

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Apimeds Pharmaceuticals US, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest APUS news & analysis

MindWave Innovations Expands U.S. Commercial Footprint with Second Agreement to Build and Operate FlashChain for New York-Based Flash Sports & Media

GlobeNewsWire · 29 Sept 2026positive

MindWave Innovations, a wholly owned subsidiary of Apimeds Pharmaceuticals US (APUS), signed a 12-month software development and technology services agreement with New York-based Flash Sports & Media Holdings to build and operate FlashChain, a blockchain for tracking digital broadcasting rights, video assets and match ticket inventory. This marks MindWave's second agreement expanding its U.S. commercial footprint.

Why it matters — APUS watchers would care because this second U.S. commercial agreement signals continued growth in MindWave's blockchain technology business under the APUS umbrella.

Apimeds Pharmaceuticals Stock Skyrockets Thursday: What's Happening?

Benzinga · 24 Sept 2026positive

Apimeds Pharmaceuticals US Inc. shares surged Thursday after its wholly owned subsidiary, MindWave Innovations Inc., announced a 12-month technology services agreement with Singapore-based AQUAE Holdings Pte. Ltd. to build and operate AQUAEChain.

Why it matters — A new commercial technology services deal through the company's subsidiary could expand Apimeds' business beyond its core pharmaceutical operations.

MindWave Innovations Signs Agreement to Build and Operate AQUAEChain, a Platform for Insured ALCI Credits

GlobeNewsWire · 24 Sept 2026neutral

MindWave Innovations announced an agreement to build and operate AQUAEChain, a platform for insured ALCI credits. MindWave will supply and operate the technology, while AQUAE leads the ALCI Credits methodology, brand, and market development.

Why it matters — This item concerns an unrelated technology partnership and has no apparent bearing on Apimeds Pharmaceuticals US, Inc. (APUS).

IBN Initiates Coverage of Apimeds Pharmaceuticals US, Inc.

GlobeNewsWire · 18 Sept 2026neutral

IBN announced that it has initiated coverage of Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS), which has engaged IBN to assist with its corporate communications strategy. The announcement was made via GlobeNewsWire from Austin, Texas.

Why it matters — APUS watchers may gain increased visibility and communication support for the company through this newly engaged financial news and publishing relationship.

NILA Token Now Available to Eligible U.S. Users on Webot, a Licensed U.S. Cryptocurrency Exchange

GlobeNewsWire · 3 Aug 2026positive

MindWave Innovations Inc., a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (APUS), announced that its NILA token is now available to eligible U.S. users on Webot, a licensed U.S. cryptocurrency exchange. This marks the first time eligible U.S. users can access NILA through a licensed American platform.

Why it matters — APUS watchers would care because its subsidiary's NILA token has gained its first availability to eligible U.S. users on a licensed American cryptocurrency exchange, expanding the token's U.S. market access.

FAQ

Frequently asked questions about APUS stock

How does Ticker Nerd's model rank APUS?

As at 7 Oct 2026, Apimeds Pharmaceuticals US, Inc. ranks 12 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (92 of 100).

What is the APUS stock forecast for 2030?

No analyst covering Apimeds Pharmaceuticals US, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for APUS are extrapolating price history, which says nothing about the business.

What does Apimeds Pharmaceuticals US, Inc. do?

Apimeds Pharmaceuticals US Inc. is a clinical-stage biopharmaceutical company focused on developing Apitox, a purified bee venom-based therapeutic candidate delivered intradermally.

What is the latest news on APUS?

The most recent item we track (GlobeNewsWire, 29 Sept 2026): "MindWave Innovations Expands U.S. Commercial Footprint with Second Agreement to Build and Operate FlashChain for New York-Based Flash Sports & Media". MindWave Innovations, a wholly owned subsidiary of Apimeds Pharmaceuticals US (APUS), signed a 12-month software development and technology services agreement with New York-based Flash Sports & Media Holdings to build and operate FlashChain, a blockchain for tracking digital broadcasting rights, video assets and match ticket inventory. This marks MindWave's second agreement expanding its U.S. commercial footprint.

Company

About Apimeds Pharmaceuticals US, Inc.

Apimeds Pharmaceuticals US Inc. is a clinical-stage biopharmaceutical company focused on developing Apitox, a purified bee venom-based therapeutic candidate delivered intradermally. The company is primarily working on treatments for inflammation and pain management, with an emphasis on knee osteoarthritis and, to a lesser extent, multiple sclerosis. Its current business centers on advancing this non-narcotic drug candidate through clinical development and related pharmaceutical activities. Apimeds Pharmaceuticals US Inc. also operates as part of a broader biopharmaceutical platform that includes research, development, and potential commercialization capabilities. Headquartered in Matawan, New Jersey, the company is positioned within the specialty drug manufacturing and biotechnology markets, where its work targets high-need conditions in musculoskeletal and inflammatory care.

CEO Dr. Vinod Menon · 2 employees · United States · https://www.mindwavedao.com